The unmet drug development need:

Drug development costs have increased 4 fold in the last 20 years while the number of medications reaching the market each year has dropped by 50%. However, the discovery of molecules demonstrating therapeutic potential has greatly increased, identifying a serious problem in the drug development process.

The main reasons for drug development failure are:

• Unexpected toxicity sometimes discovered only in late stage clinical trials or post commercialisation. Such potential for toxicity needs to be identified in the discovery or preclinical development stages.

• The difficulty of demonstrating the efficacy of promising products due to the diversity of the study population.

ICDD's solutions

Our proprietary technologies address these unmet needs in two ways:

• With the aid of proprietary technologies, ICDD-sas is able to predict chronic toxicity at an early stage of product development, using in vitro and in vivo human mitochondrial behavior as a safety index. This approach reduces the need for animal toxicity testing.

• ICDD is able to identify patient sub-groups in which efficacy of chronic evolving disease treatments will be the greatest, with the aid of proprietary biomarkers discovered using an innovative patent-protected method of cell surface protein enrichment.

ICDD's customersWe provide product development services for:

• The biopharmaceutical industry

• Cosmetic companies

• Nutraceutical companies